PDS Biotechnology Receives Nasdaq Notice for Low $1.00 Bid Price

What Happened
PDS Biotechnology Corporation (NASDAQ: PDSB) filed an 8‑K reporting that on July 30, 2026 Nasdaq’s Listing Qualifications Department sent a deficiency letter notifying the company that the closing bid price for its common stock has been below the $1.00 minimum required under Nasdaq Listing Rule 5550(a)(2) for the last 30 consecutive business days. The letter does not immediately affect the listing and PDSB will continue trading under the symbol “PDSB.”

Key Details

• Nasdaq provided a 180‑calendar‑day compliance period under Rule 5810(c)(3)(A), giving PDSB until January 26, 2027 to regain a $1.00 closing bid price.
• Regaining compliance requires a closing bid of at least $1.00 for a minimum of 10 consecutive business days during the 180‑day period.
• If PDSB fails to regain compliance, it may be eligible for a second 180‑day period only if it meets other listing standards (including market value of publicly held shares) and notifies Nasdaq of its intent to cure.
• The company noted potential remedies it may consider, such as a reverse stock split, and that it could appeal any delisting determination to a Nasdaq hearings panel.

Why It Matters
This notice signals a risk of delisting if PDSB’s share price does not meet Nasdaq’s minimum bid requirement within the compliance window. Delisting could reduce liquidity, limit investor access, and impose additional costs or disclosure requirements. The company continuing to trade for now means investors still have time to monitor developments or corporate actions (e.g., reverse split) intended to restore compliance.